AstraZeneca Aktie 163523 / US0463531089
64.42
USD
-0.22
USD
-0.34%
19.12.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
AstraZeneca Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | AstraZeneca PLC (spons. ADRs) | 2.11 | 1.42 | USD |
| 2022 | AstraZeneca PLC (spons. ADRs) | 2.09 | 1.42 | USD |
| 2021 | AstraZeneca PLC (spons. ADRs) | 2.41 | 1.41 | USD |
| 2020 | AstraZeneca PLC (spons. ADRs) | 2.74 | 1.37 | USD |
| 2019 | AstraZeneca PLC (spons. ADRs) | 2.75 | 1.37 | USD |
| 2018 | AstraZeneca PLC (spons. ADRs) | 3.61 | 1.37 | USD |
| 2017 | AstraZeneca PLC (spons. ADRs) | 3.95 | 1.37 | USD |
| 2016 | AstraZeneca PLC (spons. ADRs) | 5.01 | 1.37 | USD |
| 2015 | AstraZeneca PLC (spons. ADRs) | 4.04 | 1.37 | USD |
| 2014 | AstraZeneca PLC (spons. ADRs) | 3.95 | 1.39 | USD |
Gewinn je Aktie- AstraZeneca
| 1.9 23 | 1.1 22 | 0.0 21 | 1.2 20 | 0.5 19 | 0.8 18 | 1.2 17 |
Umsatz je Aktie- AstraZeneca
| 14.7 23 | 14.2 22 | 13.3 21 | 10.5 20 | 9.4 19 | 8.7 18 | 8.9 17 |
KGV- AstraZeneca
| 35.0 23 | 63.8 22 | 1475 21 | 41.0 20 | 97.2 19 | 44.7 18 | 29.3 17 |
AstraZeneca PLC (spons. ADRs): Die Aktie (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 1.92 | 1.06 | 0.04 | 1.22 | 0.52 | 0.85 | 1.19 |
| Gewinn je Aktie unverwässert | 1.92 | 1.06 | 0.04 | 1.22 | 0.51 | 0.85 | 1.19 |
| Gewinn je Aktie verwässert | 1.91 | 1.05 | 0.04 | 1.22 | 0.51 | 0.85 | 1.19 |
| Dividende pro Aktie | 1.42 | 1.42 | 1.41 | 1.37 | 1.37 | 1.37 | 1.37 |
| Gesamtdividendenausschüttung in Mio. | 4’481.00 | 4’364.00 | 3’856.00 | 3’572.00 | 3’592.00 | 3’484.00 | 3’519.00 |
AstraZeneca PLC (spons. ADRs): Unternehmenskennzahlen (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 14.66 | 14.22 | 13.26 | 10.51 | 9.37 | 8.72 | 8.87 |
| KGV (Jahresendkurs, EPS unverwässert) | 35.04 | 63.84 | 1’474.68 | 41.04 | 97.17 | 44.66 | 29.28 |
| KGV (Jahresendkurs, EPS verwässert) | 35.33 | 64.34 | 1’485.97 | 41.07 | 97.17 | 44.66 | 29.28 |
| KGV (Jahresendkurs) | 35.04 | 63.84 | 1’474.68 | 41.04 | 97.17 | 44.66 | 29.28 |
| Dividendenrendite Jahresende in % | 2.11 | 2.09 | 2.41 | 2.74 | 2.75 | 3.61 | 3.95 |
| Eigenkapitalquote in % | 38.73 | 38.41 | 37.29 | 23.44 | 23.78 | 23.16 | 26.27 |
| Fremdkapitalquote in % | 61.27 | 61.59 | 62.71 | 76.56 | 76.22 | 76.84 | 73.73 |
AstraZeneca PLC (spons. ADRs): GuV (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 45’811.00 | 44’351.00 | 37’833.00 | 27’594.00 | 24’384.00 | 22’090.00 | 22’465.00 |
| Umsatzveränderung in % | 3.29 | 17.23 | 37.11 | 13.16 | 10.38 | -1.67 | -2.33 |
| Bruttoergebnis vom Umsatz | 33’877.00 | 28’102.00 | 23’041.00 | 20’422.00 | 17’642.00 | 15’856.00 | 16’648.00 |
| Bruttoergebnisveränderung in % | 20.55 | 21.97 | 12.82 | 15.76 | 11.26 | -4.76 | -4.49 |
| Operatives Ergebnis | 9’411.00 | 5’060.00 | 2’864.00 | 4’685.00 | 2’807.00 | 1’836.00 | 3’471.00 |
| Veränderung Operatives Ergebnis in % | 85.99 | 76.68 | -38.87 | 66.90 | 52.89 | -47.10 | -2.58 |
| Ergebnis vor Steuern | 6’911.00 | 2’506.00 | -201.00 | 3’943.00 | 1’664.00 | 2’106.00 | 2’282.00 |
| Veränderung Ergebnis vor Steuern in % | 175.78 | - | - | 136.96 | -20.99 | -7.71 | -36.35 |
| Ergebnis nach Steuer | 5’955.00 | 3’288.00 | 112.00 | 3’196.00 | 1’335.00 | 2’155.00 | 3’001.00 |
| Veränderung Ergebnis nach Steuer in % | 81.11 | 2’835.71 | -96.50 | 139.40 | -38.05 | -28.19 | -14.23 |
AstraZeneca PLC (spons. ADRs): Bilanz (in Mio. USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 61’953 | 59’425 | 66’076 | 51’091 | 46’781 | 46’607 | 46’712 |
| Langzeit Gesamtverbindlichk. pro Aktie | - | - | - | 11.73 | 10.92 | 11.96 | 11.98 |
| Eigenkapital | 39’166 | 37’058 | 39’287 | 15’638 | 14’596 | 14’044 | 16’642 |
| Veränderung Eigenkapital in % | 5.69 | -5.68 | 151.36 | 19.01 | 5.29 | -16.66 | 0.71 |
| Bilanzsumme | 101’119 | 96’483 | 105’363 | 66’729 | 61’377 | 60’651 | 63’354 |
| Veränderung Bilanzsumme in % | 4.80 | -8.43 | 57.90 | 8.72 | 1.20 | -4.27 | 1.32 |
AstraZeneca PLC (spons. ADRs): Sonstige Angaben (in USD)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 1.92 | 1.06 | 0.04 | 1.22 | 0.51 | 0.85 | 1.19 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 81.00 | 2’588.61 | -96.76 | 137.38 | -39.66 | -28.24 | -14.44 |
| Gewinn je Aktie (verwässert) | 1.91 | 1.05 | 0.04 | 1.22 | 0.51 | 0.85 | 1.19 |
| Veränderung Gewinn je Aktie (verwässert) in % | 80.89 | 2’588.27 | -96.78 | 137.21 | -39.66 | -28.24 | -14.13 |
| Anzahl Mitarbeiter | 89’900 | 83’500 | 83’100 | 76’100 | 70’600 | 64’400 | 61’100 |
| Veränderung Anzahl Mitarbeiter in % | 7.66 | 0.48 | 9.20 | 7.79 | 9.63 | 5.40 | 2.35 |
AstraZeneca PLC (spons. ADRs) Termine
| Unternehmen | Event | Datum |
|---|---|---|
| AstraZeneca PLC (spons. ADRs) | Quartalszahlen | 06.02.2025 |
| AstraZeneca PLC (spons. ADRs) | Quartalszahlen | 25.04.2025 |
| AstraZeneca PLC (spons. ADRs) | Quartalszahlen | 24.07.2025 |
| AstraZeneca PLC (spons. ADRs) | Quartalszahlen | 06.11.2025 |
AstraZeneca PLC (spons. ADRs) vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 12.11.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 25.07.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 25.04.2024 |
| Hauptversammlung | Annual General Meeting | 11.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 08.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 09.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 28.07.2023 |
| Hauptversammlung | Annual General Meeting | 27.04.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 27.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 09.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 10.11.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 29.07.2022 |
| Hauptversammlung | Annual General Meeting | 29.04.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 29.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 10.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.97 |
| PRIMECAP Management Co. | 1.35 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 1.19 |
| Capital Research & Management Co. (International Investors) | 1.19 |
| Wellington Management Co. LLP (Wellington Breakout) | 1.15 |
| T. Rowe Price International Ltd. | 0.84 |
| Vanguard PRIMECAP Fund | 0.83 |
| Washington Mutual Investors Fund | 0.76 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 61’100 | 64’400 | 70’600 | 76’100 | 83’100 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.37 | 0.34 | 0.35 | 0.36 | 0.46 |
Bilanz (in Mio. USD) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 12’884 | 15’518 | 15’563 | 19’544 | 26’244 |
| Summe Anlagevermögen | 50’470 | 45’133 | 45’814 | 47’185 | 79’119 |
| Summe Aktiva | 63’354 | 60’651 | 61’377 | 66’729 | 105’363 |
Bilanz (in Mio. USD) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 46’712 | 46’607 | 46’781 | 51’091 | 66’076 |
| Summe Eigenkapital | 16’642 | 14’044 | 14’596 | 15’638 | 39’287 |
| Summe Passiva | 63’354 | 60’651 | 61’377 | 66’729 | 105’363 |
Adresse
| Cambridge Biomedical Campus, CB2 0AA Cambridge | |
| Telefon | +44 (20) 3749-5000 |
| URL | http://www.astrazeneca.co.uk |
Management
|
Adrian Charles Noel Kemp
Secretary |
|
Alberto Hegewisch
Chief Medical Officer |
|
Andreas Rummelt
Non-Executive Director |
|
Anna Olive Magdelene Manz
Non-Executive Director |
|
Aradhana Sarin
Chief Financial Officer & Executive Director |
|
Cindy L. Hoots
Chief Digital & Information Officer |
|
David Fredrickson
Executive Vice President-Oncology Business Unit |
|
Deborah DiSanzo
Independent Non-Executive Director |
|
Diana Layfield
Non-Executive Director |
|
Euan A. Ashley
Non-Executive Director |
|
Helen MacPhee
Vice President |
|
Iskra Reic
Executive Vice President-International Operations |
|
Jeffrey Pott
CHRO, Chief Compliance Officer & General Counsel |
|
Jonathan Thomas Charles Slade
Group Treasurer |
|
Kevin G. Lokay
Head-Change Implementation |
|
Marc Pierre Jean Dunoyer
Chief Strategy Officer |
|
Marcus Wallenberg
Independent Non-Executive Director |
|
Margareta Elisabeth Björk
Senior VP & Head-Late Stage Development |
|
Michel Demaré
Chairman |
|
Nazneen Rahman
Independent Non-Executive Director |
|
Pam P. Cheng
Executive VP-Operations & Information Technology |
|
Pascal Soriot
Chief Executive Officer & Executive Director |
|
Philip Arthur John Broadley
Senior Independent Non-Executive Director |
|
Regina Fritsche-Danielson
SVP, Head-Research & Early Development |
|
Ruud Dobber
Executive VP-Biopharmaceuticals Business |
|
Sharon Barr
EVP-BioPharmaceuticals Research & Development |
|
Sherilyn D. McCoy
Independent Non-Executive Director |
|
Shu Kam Mok
Independent Non-Executive Director |
|
Sjoerd Hubben
Vice President-Global Government Affairs & Policy |
|
Susan Mary Galbraith
Executive VP-Oncology Research & Development |
|
Tyrell J. Rivers
Executive Director-Corporate Development |